Continuous subcutaneous foslevodopa/foscarbidopa: final results from a Phase 3, open-label study

J. Aldred; A. Amelin; A. Antonini; B. Bergmans; F. Bergquist; M. Bouchard; K. Budur; C. Carroll; K. Chaudhuri; S. Criswell; E. Danielsen; E. Freire Alvarez; F. Gandor; J. Jia; T. Kimber; H. Mochizuki; W. Robieson; A. Spiegel; D. Standaert; S. Talapala; M. Facheris; V. Fung

Continuous subcutaneous foslevodopa/foscarbidopa: final results from a Phase 3, open-label study

J. Aldred, A. Amelin, A. Antonini, B. Bergmans, F. Bergquist, M. Bouchard, K. Budur, C. Carroll, K. Chaudhuri, S. Criswell, E. Danielsen, E. Freire Alvarez, F. Gandor, J. Jia, T. Kimber, H. Mochizuki, W. Robieson, A. Spiegel, D. Standaert, S. TalapalaM. Facheris, V. Fung

Macquarie University Clinical Associates (MUCA)

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Pages (from-to)	S8
Number of pages	1
Journal	Movement Disorders
Volume	38
Issue number	Supplement 1
Publication status	Published - Aug 2023
Event	International Congress of Parkinson's Disease and Movement Disorders - Copenhagen, Denmark Duration: 27 Aug 2023 → 31 Aug 2023

Cite this

Aldred, J., Amelin, A., Antonini, A., Bergmans, B., Bergquist, F., Bouchard, M., Budur, K., Carroll, C., Chaudhuri, K., Criswell, S., Danielsen, E., Alvarez, E. F., Gandor, F., Jia, J., Kimber, T., Mochizuki, H., Robieson, W., Spiegel, A., Standaert, D., ... Fung, V. (2023). Continuous subcutaneous foslevodopa/foscarbidopa: final results from a Phase 3, open-label study. Movement Disorders, 38(Supplement 1), S8.

@article{e890cdf509b44158a5a765dfbac19768,

title = "Continuous subcutaneous foslevodopa/foscarbidopa: final results from a Phase 3, open-label study",

author = "J. Aldred and A. Amelin and A. Antonini and B. Bergmans and F. Bergquist and M. Bouchard and K. Budur and C. Carroll and K. Chaudhuri and S. Criswell and E. Danielsen and Alvarez, {E. Freire} and F. Gandor and J. Jia and T. Kimber and H. Mochizuki and W. Robieson and A. Spiegel and D. Standaert and S. Talapala and M. Facheris and V. Fung",

year = "2023",

month = aug,

language = "English",

volume = "38",

pages = "S8",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley & Sons",

number = "Supplement 1",

note = "International Congress of Parkinson's Disease and Movement Disorders ; Conference date: 27-08-2023 Through 31-08-2023",

}

Aldred, J, Amelin, A, Antonini, A, Bergmans, B, Bergquist, F, Bouchard, M, Budur, K, Carroll, C, Chaudhuri, K, Criswell, S, Danielsen, E, Alvarez, EF, Gandor, F, Jia, J, Kimber, T, Mochizuki, H, Robieson, W, Spiegel, A, Standaert, D, Talapala, S, Facheris, M & Fung, V 2023, 'Continuous subcutaneous foslevodopa/foscarbidopa: final results from a Phase 3, open-label study', Movement Disorders, vol. 38, no. Supplement 1, pp. S8.

TY - JOUR

T1 - Continuous subcutaneous foslevodopa/foscarbidopa

T2 - International Congress of Parkinson's Disease and Movement Disorders

AU - Aldred, J.

AU - Amelin, A.

AU - Antonini, A.

AU - Bergmans, B.

AU - Bergquist, F.

AU - Bouchard, M.

AU - Budur, K.

AU - Carroll, C.

AU - Chaudhuri, K.

AU - Criswell, S.

AU - Danielsen, E.

AU - Alvarez, E. Freire

AU - Gandor, F.

AU - Jia, J.

AU - Kimber, T.

AU - Mochizuki, H.

AU - Robieson, W.

AU - Spiegel, A.

AU - Standaert, D.

AU - Talapala, S.

AU - Facheris, M.

AU - Fung, V.

PY - 2023/8

Y1 - 2023/8

UR - https://doi.org/10.1002/mds.29537

M3 - Meeting abstract

SN - 0885-3185

VL - 38

SP - S8

JO - Movement Disorders

JF - Movement Disorders

IS - Supplement 1

Y2 - 27 August 2023 through 31 August 2023

ER -

Continuous subcutaneous foslevodopa/foscarbidopa: final results from a Phase 3, open-label study

Other files and links

Cite this